Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharma Industry Likely To Take Wait-And-See Approach To GSK U.S. Sales Incentive Changes

Executive Summary

Like the canaries that miners used to take deep into the coal mines with them to ensure the air was of breathing quality, GlaxoSmithKline sales representatives will play a pioneering role starting next year when new compensation practices based not on sales totals but instead on customer service are implemented

You may also be interested in...

Biopharma Sizes Up The Affordable Care Act: Buyer’s Remorse Or Winner’s Curse?

Three years into the ACA, the biopharma industry takes stock of its near-term wins and losses as the law’s critical expanded insurance coverage takes effect beginning in 2014. Pharma still isn’t sure whether the increase in covered lives from the exchanges will boost prescription sales enough to offset the rebates, taxes, and fees it agreed to pay out, or what kind of patients constitute this new market.

GSK’s New Commercial Model Will “Stay The Course” Regardless Of ACA’s Future

About a year into GSK’s innovative sales force incentive program, Jack Bailey, head of payers, policy and vaccines, provides an update on the company’s strategy in an interview with “The Pink Sheet” DAILY.

GSK Finds Role For Drug Sales Reps In A Digital World

GlaxoSmithKline exec Deidre Connelly and other panelists at the PDR Network’s PharmEHR Summit describe how sales reps can complement the information now available to physicians electronically at the point of prescribing.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts